4/A: Vita Coco CEO Sells $2M in Shares
Insider Transaction Report Amendment
Vita Coco Company CEO Martin Roper and related family trusts sold over 50,000 shares of common stock for approximately $2 million through a pre-arranged 10b5-1 trading plan.
Summary
- Martin Roper, Chief Executive Officer and 10% owner of Vita Coco Company, Inc. (COCO), reported sales of common stock in an amended Form 4 filing.
- A total of 50,506 shares were sold between September 15, 2025, and September 17, 2025.
- The sales were executed at weighted average prices ranging from approximately $40.00 to $40.54 per share.
- These transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-scheduled sales.
- Following these transactions, Martin Roper directly holds 339,297 shares and indirectly holds 273,806 shares via the Christopher G. Roper Exempt Family Trust, 272,915 shares via the Peter S. Roper Exempt Family Trust, and 273,931 shares via the Thomas L. Roper Exempt Family Trust.
- Roper also holds various non-qualified stock options, including 579,670 and 40,950 fully vested options at an exercise price of $10.178, among others with different vesting schedules and exercise prices.
Sentiment
Score: 4
Explanation: The filing reports significant insider selling by the CEO and related trusts. While conducted under a 10b5-1 plan, which mitigates concerns about opportunistic timing, substantial insider selling can still be perceived negatively by the market as it reduces management's direct stake in the company. The amendment itself doesn't change the nature of the transactions, only corrects or clarifies the original filing.
Negatives
- Insider selling by the CEO and related family trusts, totaling 50,506 shares, could be perceived negatively by investors as it reduces insider ownership.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Sales of common stock by the Christopher G. Roper Exempt Family Trust, Peter S. Roper Exempt Family Trust, and Thomas L. Roper Exempt Family Trust are considered related party transactions as Martin Roper is the reporting person and likely has influence or beneficial interest in these trusts.
Stakeholder Impact
- Shareholders: The sale of shares by the CEO and related trusts could be interpreted as a lack of confidence or a move to diversify, potentially leading to negative sentiment or downward pressure on the stock price. However, the 10b5-1 plan suggests a pre-planned, non-discretionary sale.
Key Dates
| Date | Description |
|---|---|
| 09/15/2025 | Transaction date for initial sales of common stock by Martin Roper and related trusts. |
| 09/16/2025 | Transaction date for additional sales of common stock by Martin Roper and related trusts. |
| 09/17/2025 | Transaction date for final sales of common stock by Martin Roper and related trusts. |
| 09/18/2025 | Date of original Form 4 filing. |
| 09/23/2025 | Date of this amended Form 4/A filing. |
| 11/27/2022 | Start date for vesting of a non-qualified stock option with an exercise price of $15.00. |
| 03/10/2024 | Start date for vesting of a non-qualified stock option with an exercise price of $16.91. |
| 03/04/2025 | Start date for vesting of a non-qualified stock option with an exercise price of $26.18. |
| 03/03/2026 | Start date for vesting of a non-qualified stock option with an exercise price of $32.78. |
| 09/19/2029 | Expiration date for a non-qualified stock option with an exercise price of $10.178. |
| 01/11/2031 | Expiration date for a non-qualified stock option with an exercise price of $10.178. |
| 10/21/2031 | Expiration date for a non-qualified stock option with an exercise price of $15.00. |
| 03/10/2033 | Expiration date for a non-qualified stock option with an exercise price of $16.91. |
| 03/04/2034 | Expiration date for a non-qualified stock option with an exercise price of $26.18. |
| 03/03/2035 | Expiration date for a non-qualified stock option with an exercise price of $32.78. |
Recommendation
holdWhile the significant insider selling by the CEO and related trusts might raise concerns, the transactions were executed under a pre-arranged 10b5-1 trading plan, which suggests a planned divestment rather than a reaction to new negative information. The stock options held by the CEO also indicate continued long-term interest. Investors should monitor future filings and company performance, but this specific filing, being an amendment to a pre-scheduled sale, does not warrant an immediate 'sell' or 'buy' recommendation based solely on this information. A 'hold' stance is appropriate to observe broader company fundamentals and market sentiment.
Keywords
Vita Coco Company, COCO, Martin Roper, Insider Trading, SEC Form 4/A, Stock Sale, 10b5-1 Plan, CEO, Beneficial Ownership, Coconut Water
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.